MCF Advisors LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

MCF Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,348 shares of the biopharmaceutical company’s stock after purchasing an additional 152 shares during the quarter. MCF Advisors LLC’s holdings in Gilead Sciences were worth $538,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Tompkins Financial Corp grew its position in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares in the last quarter. Private Wealth Management Group LLC bought a new stake in Gilead Sciences in the fourth quarter valued at $29,000. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $30,000. Finally, Rakuten Securities Inc. bought a new stake in Gilead Sciences in the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.3 %

Shares of Gilead Sciences stock traded down $0.22 during trading on Friday, hitting $68.61. 9,590,049 shares of the stock traded hands, compared to its average volume of 9,497,302. The company has a fifty day moving average price of $65.98 and a two-hundred day moving average price of $72.64. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The stock has a market cap of $85.48 billion, a P/E ratio of 190.58, a PEG ratio of 2.93 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.37 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on GILD shares. Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Maxim Group cut their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research report on Friday, June 14th. Barclays reduced their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Finally, Oppenheimer reiterated an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $83.47.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.